[go: up one dir, main page]

NZ329694A - Use of isolated cytolytic T cell clone specific for a complex of HLA-A2 and a peptide which complexes with HLA-A2 to treat cancer - Google Patents

Use of isolated cytolytic T cell clone specific for a complex of HLA-A2 and a peptide which complexes with HLA-A2 to treat cancer

Info

Publication number
NZ329694A
NZ329694A NZ329694A NZ32969495A NZ329694A NZ 329694 A NZ329694 A NZ 329694A NZ 329694 A NZ329694 A NZ 329694A NZ 32969495 A NZ32969495 A NZ 32969495A NZ 329694 A NZ329694 A NZ 329694A
Authority
NZ
New Zealand
Prior art keywords
hla
complex
peptide
cell clone
complexes
Prior art date
Application number
NZ329694A
Inventor
Der Bruggen Pierre Van
Thierry Boon-Falleur
Catia Traversari
Katharina Fleischauer
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/217,187 external-priority patent/US5554506A/en
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of NZ329694A publication Critical patent/NZ329694A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Method for treating a non-human subject with a cancerous condition characterised by cancer cells which present a complex of HLA-A2 and a peptide molecule selected from SEQ ID NO:3 and SEQ ID NO: 4 on their surfaces, comprising administering an amount of an isolated cytolytic T cell clone specific for a complex of HLA-A2 and peptide selected from the group consisting of SEQ ID NO: 3 and SEQ ID NO: 4 to the subject to lyse cancerous cells.
NZ329694A 1994-03-24 1995-03-21 Use of isolated cytolytic T cell clone specific for a complex of HLA-A2 and a peptide which complexes with HLA-A2 to treat cancer NZ329694A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/217,187 US5554506A (en) 1994-03-24 1994-03-24 Isolated, MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
NZ283543A NZ283543A (en) 1994-03-24 1995-03-21 Isolated mage-3 (tumour rejection antigen) derived peptides which complex with hla-a2 molecules and their use

Publications (1)

Publication Number Publication Date
NZ329694A true NZ329694A (en) 2000-04-28

Family

ID=26651573

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ329694A NZ329694A (en) 1994-03-24 1995-03-21 Use of isolated cytolytic T cell clone specific for a complex of HLA-A2 and a peptide which complexes with HLA-A2 to treat cancer

Country Status (1)

Country Link
NZ (1) NZ329694A (en)

Similar Documents

Publication Publication Date Title
NZ329695A (en) Use of isolated rejection antigen precursor MAGE-2 derived peptide in treating cancer
舒良树 et al. Study of the high pressure metamorphic blueschist and its Late Proterozoic age in the eastern Jiangnan belt
MXPA01004648A (en) Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody.
ES8607732A1 (en) Implantable controlled-release preparations of regulatory peptides, and process for their preparation.
NZ210194A (en) Pentapeptides with thymopoietin and splenin like activity
IL144559A0 (en) Antibodies for cancer therapy and diagnosis
TW200606176A (en) Compositions and methods for wt1 specific immunotherapy
GR3024489T3 (en)
ZA952376B (en) Isolated MAGE-3 derived peptides which complex with HLA-A2 molecules and uses thereof
EP0552296A4 (en) Mouse monoclonal antibodies
EP1007537A4 (en) Receptor protein designated 2f1
CA2132001A1 (en) Methods of treating cancer using modified c-reactive protein
CA2186004A1 (en) Isolated peptides derived from mage tumor rejection antigen precursors which complex with hla-a2 molecules
GR3024379T3 (en) Peptides with organo-protective activity, the process for preparing them and their use in therapy
FR2662698B1 (en)
ES8403157A1 (en) A method of manufacturing biological active substance.
DE69720783D1 (en) REACTIVE OXYGEN COMPOUNDS FOR THE INDUCTION OF CELL DIFFERENTIATION MALIGNER CELLS LIKE LEUKEMIA
CA2218129A1 (en) Chimeric mcp and daf proteins with cell surface localizing domain
NZ329694A (en) Use of isolated cytolytic T cell clone specific for a complex of HLA-A2 and a peptide which complexes with HLA-A2 to treat cancer
WO1992018536A3 (en) Method for detecting an localizing tissues having neurokinine 1 receptors
AU5327198A (en) Nucleotide sequence coding for a flavin-containing monooxygenase, corresponding protein and their applications in the fields of diagnosis and therapy
ES8600518A1 (en) TGF polypeptides, antigenic oligopeptides derived therefrom and antibodies produced therefrom.
EP0125125A3 (en) An agent for inhibiting the proliferation of malignant tumour cells and a process for the preparation thereof
AU5309586A (en) Polypeptide secretion-causing vector, microorganisms transformed by said vector, and process for preparing polypeptide using said microorganisms
AU5455798A (en) Gene product over expressed in cancer cells